Dutch Bridge International B.V. provides targeted, early-phase support for the European market entry of medicinal products, medical devices, in-vitro diagnostics, and advanced therapies. We address early Health Technology Assessment (HTA), strategic evidence planning, and identifying evidence gaps. By aligning preliminary cost-effectiveness models and early value propositions with anticipated European payer requirements, we support pricing strategies and establish robust reimbursement pathways to ensure sustainable market access.